Osmotica Pharmaceuticals Plc

RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.

-- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25 million --

UPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance

Osmotica Pharmaceuticals plc (NASDAQ: OSMT) will change its name to RVL Pharmaceuticals plc and start trading under the new ticker (NASDAQ: RVLP). The Company says that the rebranding reflects RVL's strategy to become a growth company in eye care and medical aesthetics.

Osmotica Pharma Announces Rebranding As RVL Pharma, Issues Q4 Sales Outlook

Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance

-- Topics include corporate name change, launch plans into the medical aesthetics market and general business updates -- -- Featured speakers include Dr. Jackie Yee and Dr. Justin Harper --

RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022

BRIDGEWATER, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and other key speakers, will host a call to discuss recent UPNEEQ ® trends, pending expansion into the medical Aesthetics market and other general business updates as follows:

Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022

BRIDGEWATER, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present virtually at the H.C. Wainwright Bioconnect Conference as follows:

Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference

Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q3 2021 Results - Earnings Call Transcript

Osmotica Pharmaceuticals (OSMT) delivered earnings and revenue surprises of -16.67% and -7.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Osmotica Pharmaceuticals (OSMT) Reports Q3 Loss, Misses Revenue Estimates

Third quarter Upneeq® product sales of $2.2 million, representing 47% growth over second quarter sales

Osmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business Update

BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Jefferies London Virtual Healthcare Conference 2021 as follows:

Osmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021

BRIDGEWATER, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that the Company will release its 2021 third quarter financial results on Monday, November 15, 2021, after the close of the U.S. financial markets.

Osmotica Pharmaceuticals plc to Provide Third Quarter 2021 Business and Financial Update on November 15, 2021

Osmotica Pharmaceuticals (OSMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Osmotica Pharmaceuticals (OSMT) to Report a Decline in Earnings: What to Look Out for

BRIDGEWATER, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that on October 12, 2021, it closed its previously announced underwritten public offering of 14,000,000 ordinary shares of the Company and warrants to purchase up to 14,000,000 ordinary shares, at a public offering price of $2.50 per share and accompanying warrant. The warrants have an exercise price of $3.10 per share, are immediately exercisable and will expire three and one-half years from the date of issuance. The Company granted the underwriter a 30-day option to purchase up to an additional 2,100,000 ordinary shares and/or warrants to purchase additional 2,100,000 ordinary shares at the public offering price, less the underwriting discounts and commissions. On October 11, 2021 the underwriter exercised its option to purchase additional warrants to purchase up to 2,100,000 ordinary shares.

Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering

The stock price of Osmotica Pharmaceuticals PLC (NASDAQ: OSMT) fell by over 35% this past week. This is why it happened.

OSMT Stock: Why It Fell By Over 35% This Week

Shares of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) tanked more than 35% on Thursday as the company priced its underwritten public offering of 14 million ordinary shares at a discount. Osmotica to generate $35 million in gross proceeds from the offering Osmotica priced its previously announced public offering at $2.50 a share that represents an about […] The post Here's why Osmotica Pharmaceuticals is down 35% on Thursday appeared first on Invezz.

Here's why Osmotica Pharmaceuticals is down 35% on Thursday

BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has entered into a note purchase agreement for up to $100 million of senior secured notes with funds managed by Athyrium Capital Management (“Athyrium”).

Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million

The stock price of Osmotica Pharmaceuticals (NASDAQ: OSMT) fell by over 40% pre-market today. This is why it happened.

OSMT Stock: Why It Substantially Fell Today

Osmotica Pharmaceuticals plc (NASDAQ: OSMT) has priced its secondary public offering of 14 million shares and warrants to purchase up to 14 million shares at $2.5/piece. Gross proceeds are expected to be $35 million.

Osmotica Under Pressure On $35M Equity Raise To Pay Off Debt

BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 14,000,000 ordinary shares of the Company and warrants to purchase up to 14,000,000 ordinary shares at a public offering price of $2.50 per share and accompanying warrant. The warrants have an exercise price of $3.10 per share, are immediately exercisable and will expire three and one-half years from the date of issuance. The Company has granted the underwriter a 30-day option to purchase up to additional 2,100,000 ordinary shares and/or additional warrants to purchase up to 2,100,000 ordinary shares, at the public offering price per share and per warrant, respectively, less the underwriting discounts and commissions.

Osmotica Pharmaceuticals Announces Pricing of $35 Million Underwritten Public Offering

BRIDGEWATER, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has commenced an underwritten public offering of its ordinary shares and warrants to purchase its ordinary shares. In addition, Osmotica expects to grant the underwriter of the offering a 30-day option to purchase additional ordinary shares and/or warrants to purchase ordinary shares (equal to 15% of the ordinary shares and/or 15% of the warrants offered in the public offering) at the public offering price per share and per warrant, respectively, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Osmotica Pharmaceuticals plc Announces Proposed Underwritten Public Offering

BRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Cantor Virtual Global Healthcare Conference 2021 as follows:

Osmotica Pharmaceuticals plc to Present at Cantor Virtual Global Healthcare Conference 2021

BRIDGEWATER, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference as follows:

Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference

-- Divestiture advances Company's transformation and emphasis on eye care and ocular aesthetics -- -- Proceeds of the sale will be used to retire a substantial portion of outstanding debt --

Osmotica Pharmaceuticals plc Closes Sale of Legacy Business to Alora Pharmaceuticals, LLC

Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q2 2021 Results - Earnings Call Transcript

OSMOTICA PHARM (OSMT) delivered earnings and revenue surprises of 0.00% and -66.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

News for Osmotica Pharmaceuticals Plc Stock (OSMT)